Disappointing trial results for Aerie Pharmaceuticals
April 24, 2015 at 12:57 PM EDT
Aerie Pharmaceuticals (Nasdaq: AERI) reported disappointing results from a Phase 3 registration trial for Rhopressa sending the stock price plummeting $21.42 to $13.97.